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ABSTRACT
Context: Abnormal angiogenesis and evasion of apoptosis are hallmarks of cancer. Accordingly, anti-
angiogenic and pro-apoptotic therapies are effective strategies for cancer treatment. Medicinal plants,
namely, Eugenia jambolana Lam. (Myrtaceae), Musa paradisiaca L. (Musaceae), and Coccinia indica Wight &
Arn. (Cucurbitaceae), have not been greatly investigated for their anticancer potential.
Objective: We investigated the anti-angiogenic and pro-apoptotic efficacy of ethyl acetate (EA) and n-
butanol (NB) extracts of E. jambolana (seeds), EA extracts of M. paradisiaca (roots) and C. indica (leaves)
with respect to mammary neoplasia.
Materials and methods: Effect of extracts (2–200lg/mL) on cytotoxicity and MCF-7, MDA-MB-231 and
endothelial cell (EC) proliferation and in vitro angiogenesis were evaluated by MTT, 3[H]thymidine uptake
and EC tube formation assays, respectively. In vivo tumour proliferation, VEGF secretion and angiogenesis
were assessed using the Ehrlich ascites tumour (EAT) model followed by rat corneal micro-pocket and
chicken chorioallantoic membrane (CAM) assays. Apoptosis induction was assessed by morphological and
cell cycle analysis.
Results: EA extracts of E. jambolana and M. paradisiaca exhibited the highest cytotoxicity (IC50 25 and
60lg/mL), inhibited cell proliferation (up to 81%), and tube formation (83% and 76%). In vivo treatment
reduced body weight (50%); cell number (16.5- and 14.7-fold), secreted VEGF (90%), neoangiogenesis in
rat cornea (2.5- and 1.5-fold) and CAM (3- and 1.6-fold) besides EAT cells accumulation in sub-G1 phase
(20% and 18.38%), respectively.
Discussion and conclusion: Considering the potent anti-angiogenic and pro-apoptotic properties, lead
molecules from EA extracts of E. jambolana and M. paradisiaca can be developed into anticancer drugs.
ARTICLE HISTORY
Received 9 August 2016
Revised 8 March 2017
Accepted 12 March 2017
KEYWORDS
Anti-angiogenic; pro-
apoptotic; cytotoxicity
Introduction
Angiogenesis involves the formation of new vasculature from the
already existing blood vessels and is a characteristic phenomenon
in numerous diseases, such as tumour formation, rheumatoid
arthritis, diabetic retinopathy and psoriasis to name a few
(Yu et al. 2009; Miao et al. 2011). This physiological process is
effected by various factors such as vascular endothelial growth
factor (VEGF), angiopoietins (Ang), platelet-derived growth fac-
tor (PDGF), matrix metalloproteinase (MMP) which expedite cell
proliferation, tube formation and migration of endothelial cells
(Carmeliet & Jain 2011; Wang et al. 2013). There is a rapid
increase in angiogenesis when a tumour transits into the malig-
nant state as a result of a process called the ‘angiogenic switch’
(Guo et al. 2013). VEGF-A is one of the critical factors respon-
sible for augmentation of the tumour vascular bed, which is
characterized by abnormal features such as high turnover of neo-
vessels, poor perfusion and increased leakage (Claesson-Welsh &
Welsh 2013). VEGF is overexpressed in hypoxic tumour cells
(Carbajo-Pescador et al. 2013); endothelial cells (ECs) and
tumour-associated macrophages (TAMs) (Guo et al. 2013). The
majority of studies have shown that VEGF signalling in tumour
cells is autocrine in nature, characteristic of more aggressive can-
cers, although paracrine signalling also occurs (Goel & Mercurio
2013).
Breast cancer, being the second most common malignancy
worldwide, with 1.7 million new cases in 2012 (Ferlay et al.
2015), is known to have a poor prognosis due to the specific pat-
tern of metastasis (Steeg 2006). High levels of VEGF mRNA or
VEGF have been reported in invasive ductal breast carcinoma
compared to benign or normal tissue (Shivakumar et al. 2009;
Ali et al. 2011). Among all the other types of invasive ductal
breast carcinomas, the most aggressive, highly metastatic and
challenging to treat is the triple-negative breast cancer (TNBC)
(Fan et al. 2006), which cannot be treated with targeted therapy
such as herceptin or tamoxifen and is bound to have the worst
prognosis (Yin et al. 2009). However, VEGF has become a poten-
tial therapeutic target in a number of solid malignancies, includ-
ing TNBC. Clinical trials are now evaluating the potential
therapeutic agents that either inhibit VEGF or block VEGFR-2
(Dent 2009; Lu et al. 2016). Thus, targeting tumour growth by
angiotherapy is considered as one of the best strategies for anti-
cancer therapy (Bikfalvi & Bicknell 2002), thereby the problems
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of cytotoxicity and chemo-resistance associated with the classical
chemotherapies can be overcome to a certain extent.
Apart from antagonizing VEGF, small molecules such as vata-
lanib, tivozanib, cediranib, and lenvatinib have been shown to
inhibit receptor tyrosine kinase (RTK) signalling (Hojjat-Farsangi
2014). A wide variety of compounds of plant origin has been
reported to exhibit anti-angiogenic activity through various
molecular pathways. Development of new small molecules is
based on the discovery of bioactive secondary plant metabolites
and new phytochemical drugs that target tumour angiogenesis
and induce apoptosis in cancer cells. Plant polyphenols, cate-
chins, flavonoids, terpenes, tannins, alkaloids and polyacetylenes
comprise the natural anti-angiogenic phytochemicals (Lu et al.
2016). Compounds such as taxol, camptothecin and combretasta-
tin have been reported to have potent anti-angiogenic properties
(Fan et al. 2006). Further, anti-angiogenic effects through inhib-
ition of VEGF signalling have been reported from dietary func-
tional foods such as genistein from soybean, epigallocatechin
gallate from green tea, and resveratrol from red grapes. With
respect to cancer therapy, a number of important new commer-
cialized drugs have been synthesized, by structural modification
of natural compounds (Gordaliza 2007).
This study was conducted to validate the effectiveness of com-
plementary and alternative medicine by evaluating the anti-
angiogenic properties of four plant extracts; ethyl acetate (EA)
and n-butanol (NB) fractions from seeds of Eugenia jambolana
Lam. (Myrtaceae), EA fraction from the roots of Musa paradi-
siaca L. (Musaceae) and EA fraction from leaves of Coccinia ind-
ica Wight & Arn. (Cucurbitaceae). Although our previous studies
have reported the antihyperglycemic and antioxidative bioactiv-
ities of these plant sources (Chatterjee et al. 2009), various other
studies have reported a myriad of biological activity that also
includes a potent anticancer activity (Baliga 2011; Pekamwar
et al. 2013; Nadumane & Timsina 2014). In order to study the
role of these extracts on tumour growth and inhibition of VEGF-
induced angiogenesis in vitro, two invasive ductal breast carcin-
oma cell lines, namely, MCF-7, MDA-MB-231 (triple-negative)
and human umbilical vein endothelial cells (HUVEC) were used.
Ehrlich ascites tumour (EAT), a murine mammary carcinoma
model was used for in vivo studies. In the current study, we
report the effect of plant extracts on tumour burden, ascites vol-
ume, tumour cell number, peritoneal angiogenesis, and VEGF
secretion in ascites. Besides, the anti-angiogenic property of the
plant extracts has also been evaluated in a non-tumour context
using corneal micro-pocket and CAM assays. Experiments to
evaluate the mode of EAT cell death was studied by nuclear
staining and cell cycle analysis. Comprehensively, out of the four
extracts, our data suggests that two extracts, namely, EA fraction
of E. jambolana and EA fraction of M. paradisiaca have promis-
ing anti-angiogenic and pro-apoptotic activity. Further, the active
molecules from these plant extracts are potential candidates for
developing alternative and complementary treatments for breast
cancer patients.
Materials and methods
Plant material collection and extraction
Fresh seeds, leaves and roots of E. Jambolana, M. paradisiaca
and C. indica were collected from rural areas of Paschim
Midnapur District, West Bengal, India in May–July 2012.
Identification of the plants was made and a voucher specimen
(HPCH No. 8, 7 and 6) was deposited in the Botany
Department, Vidyasagar University, Midnapur, India. The plant
materials were separated washed thoroughly first with tap water
then with deionized water and dried in an incubator com-
pletely at 37 C. About 900 g of dried seeds were collected from
1 kg fresh seeds, 200 g of dried leaves were collected from 1 kg
of fresh leaves and 650 g of dried roots were collected from
1 kg of fresh roots and pulverized separately in an industrial
electrical grinder. The pulverized material was macerated in
separate 20 L percolators with hydro-methanol solvent (H2O:
MeOH:: 40:60, v/v) (for each 50 g of plant part used at least
250mL of solvent) at 35 C with an intermittent stirring for
the first 2 h and left for 36 h at 37 C. This extraction process
was repeated four times using freshly prepared hydro-methanol
solvent and the final extracts were collected on the 4th day.
The extracts were then filtered first through cotton filter fol-
lowed by No. 1 Whatman filter paper. The hydro-methanol fil-
trates were vacuum evaporated using Rotavapor (HAHN-SHIN,
HS-2000NS, Hahn-Shin Scientific Co., Korea) at 38 C and
lyophilized on bench top K Lyophilizer and finally stored in
amber glass containers refrigerated under vacuum for subse-
quent fractionation.
These dried hydro-methanol extracted powders were subjected
to fractionation with laboratory grade solvents (non-polar to
polar), dried under partial vacuum at 38 C to collect the solvent
free residues. Each fraction was stored in amber glass containers
at 4 C for experimental use. The extract preparation and frac-
tionation were performed following the method described earlier
(Wagner & Bladt 1996) with slight modification.
Preparation of the plant extracts
The plant extracts (5mg); EA and NB fractions from seeds of E.
jambolana; EA fractions from the roots of M. paradisiaca and
leaves of C. indica were dissolved in 0.1% dimethyl sulfoxide
(DMSO). Then the volume was made up to 5mL with phosphate
buffered saline (PBS) and filter sterilized using a syringe filter
(Millipore, 22 microns) to give a final concentration of 1 lg/lL.
All extracts were stored at 4 C.
Animals, cell lines, and chemicals
Female Albino-Wistar rats (4–6months old) and Swiss albino
mice (6–8weeks old) were obtained from the animal house,
department of studies in Zoology, University of Mysore, Mysuru,
India. EAT cells are maintained in our laboratory and are rou-
tinely used for in vivo transplantation.
All experiments were approved by the Institutional animal
care and use committee of the University of Mysore, according
to the guidelines from the committee for purpose of control
and supervision of experiments on animals (approval number
122/GO/ReBi/S/99/CPCSEA), the government of India.
HUVECs and endothelial growth medium (EGM) were obtained
from Cambrex Biosciences, Walkersville, MD. MCF-7 and
MDA-MB-231 cell lines were from National Centre for Cell
Sciences, Pune, India. 3[H]thymidine was from Baba Atomic
Research Center, Mumbai, India. DMEM, L15, FBS and penicil-
lin-streptomycin were from Invitrogen, Carlsbad, CA. Poly-2
hydroxyethyl methacrylate (poly 2-HEMA) from Sigma-Aldrich,
St. Louis, MO, Fertilized chicken eggs were from the govern-
ment poultry farm, Bangalore, India. Matrigel was from Becton
Dickinson Labware, Bedford, MA. Recombinant vascular endo-
thelial growth factor (rVEGF165) was expressed and purified in-
house using the pET-3d-VEGF plasmid. All the other reagents
were of the highest analytical grade.
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MTT assay
MDA-MB-231 cells, growing in exponential phase were seeded
into 96-well plates (Nunc MicroWellTM) in triplicates at an initial
density of 3 104 cells per well in 100lL of complete medium.
Following 16 h incubation, filter sterilized plant extracts were
added to the culture medium at 2, 5, 10, 20, 40, 80, 100, and
200lg/mL concentrations with appropriate controls and blanks.
Cells were incubated for 24 h. Later, 20 lL MTT (5mg/mL)
reagent (Chemicon International, Inc., Temecula, CA) was added
and incubated for 4 h at 37 C. For solubilization of the resultant
formazan product, 100lL of DMSO was added. The absorbance
was measured using a multimode reader at a test wavelength of
570 nm and a reference wavelength of 630 nm. (VarioskanTM
Flash Multimode Reader, Thermo Scientific). Data obtained are
expressed as the percentage of control mean ± SEM of triplicate
values.
Cell proliferation assay using 3[H]thymidine
3[H]thymidine incorporation assay was performed as described
previously (Raj et al. 2016). To study the in vitro effect of plant
extracts on the proliferation of HUVEC, MCF-7 and MDA-MB-
231 cells, (3 104) were seeded into separate 12 well plates in
their respective growth medium and were grown for 48 h. On the
third day, cells were serum starved for 24 h in media containing
0.1% serum and treated with plant extracts (20 lg/mL) along with
rVEGF (10 ng). The negative control wells were vehicle (0.1%
DMSO) treated while the positive control wells were rVEGF
(10 ng) treated. 3[H]thymidine (1 lCi/mL), was added to each
well and incubated for 4 h. The cells were washed with PBS, high
molecular weight DNA was precipitated using 10% trichloroacetic
acid at 4 C for 30min. After two washes with ice-cold PBS, the
pellet was solubilized in 0.2N NaOH and 0.1% SDS and taken
into scintillation vials containing 5mL of scintillation cocktail.
The incorporated 3[H] radioactivity was measured using a liquid
scintillation counter (Perkin Elmer Tri-Carb 2900 TR model,
Shelton, CT). All the data expressed as the percent mean ± SEM of
triplicate values in comparison to positive control.
In vitro tube formation assay
Tube formation of HUVEC was performed to assess the effect of
plant extracts on in vitro angiogenesis as described previously
(Ramachandra et al. 2009). A flat bottomed 96 well plate (Nunc)
was coated with 50 lL of Matrigel and allowed to solidify at
37 C for 1 h. HUVECs (5 103) were seeded on the Matrigel in
100lL complete EGM medium containing vehicle (0.1% DMSO)
for the negative control, rVEGF (10 ng) for the positive control
and the four plant extracts (20 lg/mL) along with rVEGF (10 ng)
for tests were incubated for 24 h. After incubation, the enclosed
networks of complete tubes formed were quantified by enumerat-
ing the network branch points formed in randomly chosen fields
by photographing at 200magnification under an Olympus
inverted microscope (CKX40; Olympus, New York). The average
branch points were counted using image J1.49 u software
(National Institutes of Health, Bethesda, MD).
Anti-angiogenic effect of plant extracts treatment in vivo
Ehrlich ascites tumour is derived from a murine mammary car-
cinoma and is an experimental model for breast cancer. EAT
cells (5 106) were injected intraperitoneally (i.p.) into mice
(5 groups, 5n) and tumour growth was recorded every day from
the day of transplantation. To verify whether the plant extracts
inhibit tumour growth and angiogenesis mediated by EAT cells
in vivo, the four different extracts (100mg/kg body weight/day)
was injected into the peritoneum of the respective groups of EAT
bearing mice every day from the 6th day of transplantation. The
weights of the mice were monitored from the 1st day till the
12th day. On the 12th day, the animals were sacrificed and saline
(2mL) was injected (i.p.), and a small incision was made in the
abdominal wall to harvest the tumour cells along with ascites
fluid, centrifuged at 3000 g for 10min. The volume of ascites
formed in both untreated and treated mice was recorded. The
pelleted EAT cells were counted by trypan blue dye exclusion
method using a hemocytometer. The animals were dissected and
the exposed peritoneum was examined for neovascularisation
and photographed.
VEGF-enzyme linked immunosorbent assay (VEGF-ELISA)
Recombinant human VEGF165 was used to set up the standard
curve. An indirect VEGF-ELISA was performed using ascites
fluid harvested from untreated tumour bearing mice as well as
plant extracts treated mice as described previously (Lingaraju
et al. 2008). In brief, 100lL of 1:1000 diluted ascites sample
from all the treated or untreated mice were coated onto 96-well
microplate using carbonate-bicarbonate coating buffer (pH 9.6)
at 4 C overnight. Wells were washed with PBS and blocked with
blocking buffer (5% skimmed milk powder in PBS) for 2 h at
37 C, followed by incubation with the anti-VEGF165 primary
antibody (1:1000). After 2 h incubation, wells were washed,
100 lL/well of goat anti-rabbit IgG conjugated to alkaline phos-
phatase secondary antibody (1:2000) was added. Post 2 h incuba-
tion; wells were washed prior to addition of 100lL of the
substrate, p-nitrophenyl phosphate (p-NPP). After 30min, the
reaction was terminated by adding 0.1N NaOH; the absorbance
was read at 405 nm using the Infinite 200 PRO multimode plate
reader (Tecan, M€annedorf, Switzerland).
Microvessel density scoring
For the histological studies of peritoneal neovasculature, the peri-
toneal tissue was excised from all the mice of each group and
fixed in 10% formalin solution. Microtome sections (5 lm) were
made from paraffin embedded peritoneum and stained with
hematoxylin and eosin. Microvessel density was assessed using a
bright field microscope in 10 fields of the vascularized areas
under high power (40) and the average MVD/HPF was noted
and photographed at 40magnification.
Rat corneal micro-pocket assay
The corneal micro-pocket assay was performed as described by
Nagaraj et al. (2015) to assess the anti-angiogenic effect of plant
extracts in vivo. Briefly, poly 2-HEMA pellets were formulated in
ethanol 12.5% W/V. Aliquots of 10 lL of this solution was taken
on a Teflon sheet and vehicle (0.1% DMSO) for the negative
control group, rVEGF (10 ng) for positive control group and dif-
ferent plant extracts (20 lg/mL) along with rVEGF (10 ng) for
the test group were placed onto the pellet and dried overnight at
4 C. Wister rats weighing 300–350 g were anesthetized with an
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i.p. injection of ketamine (87mg/kg) and xylazine (13mg/kg).
A corneal micro-pocket was made using a sterile scalpel, with the
pocket’s base 1mm from the limbus. A single pellet was
advanced into the lamellar pocket to the limbus using corneal
forceps. Postoperatively, gentamicin eye drops were applied onto
the operated eye. On the 7th day, the rats were anesthetized
again and the corneas were photographed using a stereo binocu-
lar microscope with CCD camera attachment, Stereo Discovery
V20, Carl Zeiss, Germany. The lengths of blood vessels from the
limbus were measured using image J1.49 u software (National
Institutes of Health, Bethesda, MD).
Shell-less CAM
The shell-less CAM assay was performed according to Nataraj
and Salimath (2013) to study the effect of the plant extracts on
the neovasculature. Fertilized chicken eggs were surface sterilized
with 70% alcohol and incubated at 37 C (fan-assisted humidified
incubator). Eggs were gently rolled periodically. On day 4, eggs
were cracked open and placed onto the cling film hammocks
aseptically in a laminar hood. Egg preparation was covered with
a sterile Petri dish and transferred to humidified incubator at
37 C for 48 h. On day 6, sterile filter discs (2mm), saturated
with the plant extracts (20 lg) along with rVEGF (10 ng), rVEGF
(10 ng) alone or vehicle (0.1% DMSO) were placed directly over
a blood vessel and placed back in the incubator. After 72 h of
incubation, the membrane was examined for inhibition of neo-
vascularization. The CAM was photographed under a stereo bin-
ocular microscope at 10magnification and the total
neovascular blood vessels per unit square millimeter (mm2) were
quantified using Image J1.49 u software (National Institutes of
Health, Bethesda, MD).
Acridine orange-ethidium bromide nuclear staining
Analysis of morphological changes to assess the mode of cell
death in the in vivo treated EAT cells was performed using acrid-
ine orange and ethidium bromide (AO/EtBr) dual staining.
Briefly, EAT cells were harvested from all the groups of mice
post-treatment as mentioned earlier and first washed with 0.4%
ammonium chloride solution to remove RBCs, followed by two
rounds of PBS washes. 1mg/mL AO/EtBr mixture (10 lL) was
added to the cell pellet in PBS and 20 lL of cells were placed on
a microscopic slide with a cover slip and immediately analyzed
under a fluorescence microscope with the fluorescein filter at
40magnification (Zeiss AxioVert). Nuclei were visualized;
apoptotic cells in ten random fields were counted and
photographed.
Flow cytometric analysis of cell cycle and apoptosis
EAT cells (3 106) were seeded in a 6 well plate in complete
DMEM media and treated with plant extracts (20 lg/mL) for
24 h at 37 C and 5% CO2 along with vehicle (0.1% DMSO)
treated control. Post-treatment, the cells were washed with PBS
and fixed overnight in ice-cold 70% ethanol. After fixation,
1 106 cells were washed twice with PBS, and the cells were
resuspended in the propidium iodide (PI) staining buffer (25 lg/
mL PI; 40 lg/mL RNase and 0.03% Igepal in PBS) and analyzed
after 30min in FACS Calibur flow cytometer (Becton Dickinson,
San Jose, CA). Cells were analyzed for DNA content in triplicates
and the fraction of every cell cycle phases including the sub G1
phase was determined.
Determination of total phenol and flavonoids contents in
the effective plant extracts
The Folin-Ciocalteu’s assay was performed to measure the total
amount of polyphenol content (Andzi-Barhe et al. 2015). Eugenia
jambolana seed extract (0.25mL) and M. paradisiaca root extract
(1mg/mL) were mixed with 1.25mL Folin–Ciocalteu reagent
(0.2N diluted in methanol). Methanol was used as a reagent
blank. After 5min incubation at room temperature, 1mL of
sodium carbonate solution (75 g/L) was added. The absorbance
was measured at 765 nm after 2 h incubation at room tempera-
ture. The total phenol content was expressed as mg of Gallic acid
equivalents (GAE) per 100 g of extract.
Quantification of flavonoids was performed using alumin-
ium chloride (Andzi-Barhe et al. 2015). Different extracts
(1mg/mL) were mixed in 1mL of AlCl3 (2%). The absorbance
was measured at 415 nm after 10min of incubation. Results
were expressed as mg of Quercetin equivalents (EQ) per 100 g
of extract.
Statistics
All the experiments were performed in triplicate with a min-
imum of three replicates. The means and standard deviations
were calculated and values are expressed as mean ± SEM. The sig-
nificance of the differences among the treatments was deter-
mined using one-way analysis of variance (ANOVA). p-Values
lower than 0.05 (p< 0.05) were considered statistically significant
and those lower than 0.01 (p< 0.01) were considered extremely
significant.
Results
Cytotoxicity of extracts
The effect of different plant extracts on the metabolic activity
and consequently the cytotoxicity was assessed by the MTT
assay in MDA-MB-231 cells. Increasing concentrations of the
four plant extracts were used and the effective concentration
was calculated from the dose-response curve along with the
IC50 values. The percentage cytotoxicity in comparison to the
vehicle treated control is shown in Figure 1(a). The EA frac-
tion of E. jambolana and the EA fraction of M. paradisiaca
exhibited significant cytotoxicity with an IC50 value of 25 and
60 lg/mL, respectively. On the contrary, NB fraction of E. jam-
bolana and the EA fraction of C. indica did not exhibit any
substantial cytotoxicity.
Inhibition of cell proliferation
HUVEC, MCF-7 and MDA-MB-231 treated with or without the
four plant extracts (20 lg/mL) along with rVEGF (10 ng) for 24 h
resulted in considerable decrease in DNA synthesis as measured
by the incorporation of 3[H]thymidine, which was prominent in
cells treated with two of the plant extracts namely the EA frac-
tion of E. jambolana and the EA fraction of M. paradisiaca as
shown in Figure 1(b). Significant inhibition of up to 71.2% and
61.6% in HUVEC, 81% and 71% in MCF-7 and 77% and 75% in
case of MDA-MB-231 cells proliferation was observed,
respectively.
1492 H. R. M ET AL.
Suppression of in vitro angiogenesis
The anti-angiogenic potential of all four plant extracts was eval-
uated by the in vitro tube formation assay, mediated by
HUVECs. In the positive control wells with vehicle (0.1%
DMSO) and rVEGF (10 ng), HUVECs differentiated into an
extensive and enclosed network of tubes. However, the treatment
with plant extracts inhibited the tube formation even in presence
of rVEGF as shown in Figure 1(c,d). The degree of HUVEC
mediated angiogenesis was assessed based on the number of
branch points by the image J analysis, which revealed that among
all the four extracts the EA fraction of E. jambolana and EA frac-
tion of M. paradisiaca showed sparse tube networks and acute
inhibition of tube formation by 83 and 76%, respectively, com-
pared to rVEGF treated positive control.
Inhibition of tumour growth and neoangiogenesis in vivo
According to the results in Figure 2(a–c), the vehicle treated
EAT bearing control mice showed a steady increase in body
weight (8–10 g), the volume of ascites fluid secreted as well as
the EAT cell number over a span of 12 days. However, the mice
in the treatment groups, specifically the treatment with EA frac-
tion of E. jambolana and EA fraction of M. paradisiaca exhibited
almost 50% reduction in body weight compared to control indi-
cating the effectiveness of the extracts in the prevention of EAT
tumour growth. Concurrently a 2.3- and 2.2-fold reduction in
secreted ascites fluid along with 16.5- and 14.7-fold reduction in
viable cells in comparison to control was observed post-treatment
with the above-mentioned extracts, respectively. Although the
NB fraction of E .jambolana and EA fraction of C. indica did
show a reduction in body weight, ascites volume, and cell num-
ber, it was not on par with that of EA fraction of E. jambolana
and EA fraction of M. paradisiaca.
Decreased microvessel density (MVD)
An acute reduction in peritoneal angiogenesis was conspicuous
in treated groups of mice compared to control EAT bearing
mice, shown in Figure 2(d). The smaller capillaries and arterioles
were affected by the treatment suggesting inhibition of tumour
neoangiogenesis.
Further authentication of the angio-inhibitory effect of the
compounds was assessed by histological examination of the peri-
toneum sections by H and E staining and microscopic examin-
ation of the microvasculature. From the photomicrographs
(40magnification), (Figure 2(e)), it is evident that the MVD is
drastically reduced in the peritoneum of mice treated with the
EA fraction of E. jambolana and EA fraction of M. paradisiaca
compared to control or other treatments.
Angio-inhibitory effect of plant extracts
The rat corneal micro-pocket assay and the shell-less chorioallan-
toic membrane assay are generally used in the in vivo assessment
Figure 1. Effects of E. jambolana, M. paradisiaca, and C. indica extracts on cell proliferation. (a) The metabolic and cytotoxic response of MDA-MB-231 cells assessed by
MTT assay. MDA-MB-231 cells (3 104) were treated with plant extracts (2, 5, 10, 20, 40, 80, 100, and 200lg/mL) for 24 h, washed with PBS, incubated for 4 h with
MTT and the formazan crystals dissolved in DMSO and read at 570 nm. (b) Cell proliferation assessed by the rate of DNA synthesis using 3[H]thymidine. HUVEC, MCF-7
and MDA-MB-231 cells (3 104) were cultured in 12-well plates, serum starved and treated with plant extracts (20lg/mL) along with rVEGF (10 ng) for 24 h. Post incu-
bation for 4 h in presence of 3[H]thymidine, the DNA was harvested and rate of cell proliferation was measured in a liquid scintillation counter. (c) HUVEC tube forma-
tion assay. HUVECs (5 103) were cultured in EGM on Matrigel with plant extracts (20 lg/mL) along with rVEGF (10 ng), in a 96 well plate. After incubation for 24 h at
37 C, capillary networks were photographed and quantified (Magnification: 200). (d) Quantification of angiogenesis by counting the average number of branch
points. Data in all results presented as mean± SEM of three independent experiments; p< 0.01 and p< 0.05.
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and validation of the angio-inhibitory potential of anti-angio-
genic compounds in a non-tumour context. Results (Figure
3(a–d)) clearly indicate that the EA fraction of E. jambolana and
EA fraction of M. paradisiaca are efficient inhibitors of neovascu-
lature even in presence of rVEGF (10 ng) in vivo, both in rat cor-
nea and the CAM in comparison to rVEGF (10 ng) treated
positive control which showed extensive angiogenesis.
In the rat cornea, the effect of EA fraction of E. jambolana
and EA fraction of M. paradisiaca on the reduction of neovascu-
lature/mm2 was 2.5- and 1.5-fold, respectively. Similarly, in the
CAM assay, the reduction in the number of vascular branches
was 3- and 1.6-fold, respectively.
Inhibition of VEGF production in EAT cells
The VEGF standard curve was observed to have good linearity as
shown in Figure 4(a). The ELISA results showed elevated levels
of VEGF in the ascites fluid taken from the tumour-bearing con-
trol mice (721 ng). However, a significant decrease (90%) in
VEGF levels was observed in the groups treated with EA fraction
of E. jambolana (13 ng) and EA fraction of M. paradisiaca
(17 ng). But groups treated with NB fraction of E. jambolana and
EA fraction of C. indica showed a comparatively lower decrease
in VEGF levels of 96 and 93 ng, respectively, (Figure 4(b)), sug-
gesting the inhibition of VEGF secretion in vivo.
Effects of plant extracts treatment in vivo on EAT cell
morphology
EAT cells, post-harvest from treated and control groups were
dual stained with acridine orange and ethidium bromide and
examined under a fluorescent microscope. No significant mor-
phological changes were observed in the vehicle-treated control
cells, most of them appeared green with intact nuclei. However,
Figure 2. Effects of plant extracts on tumour growth and angiogenesis in vivo. (a) Body weights of EAT-bearing; untreated and treated with plant extracts were
recorded. 6th day onwards, plant extracts (100mg/kg body weight) was administered (i.p) for six days. The animals were sacrificed on the 12th day. EAT cells were col-
lected along with ascites fluid and centrifuged, (b) secreted ascited volume, (c) EAT cell count assessed by trypan blue dye exclusion method, (d) representative photo-
graphs of the peritoneum of the untreated and treated mice and (e) peritoneal MVD marked by arrows in each peritoneum assessed by H and E staining of sections.
At least five mice were used in each group and the results obtained are an average of three individual experiments and means of ± S.E.M. n¼ 5 per group.
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the cells from the treated groups showed the early and late stages
of apoptosis, manifested by the shrunken and crescent-shaped
orange nuclei, membrane blebbing and apoptotic bodies contain-
ing fragmented nuclei. The percentage of apoptotic cells was
determined by counting the number of apoptotic cells under the
microscope in ten random fields in comparison to the vehicle
treated control. Results, (Figure 5(a,c)) clearly show increased
apoptosis induction by 51% and 56% by the EA fraction of E.
jambolana and EA fraction of M. paradisiaca treatments,
respectively.
Plant extracts induce apoptosis without cell cycle arrest
The inhibitory effect of plant extracts on EAT cell proliferation
was ascertained by cell cycle analysis by flow cytometry. EAT
cells; post-treatment with plant extracts for 24 h, the cell cycle
distribution was analyzed by flow cytometry following staining
with propidium iodide (PI). A significant accumulation of cells
was observed in sub-G1 phase in cells treated with EA fraction
of E. jambolana (20%) and EA fraction of M. paradisiaca
(18.38%), characteristic of apoptosis, whereas treatments with NB
fraction of E. jambolana and EA fraction of C. indica showed
7.53% and 0.94%, respectively as shown in Figure 5(b,d).
However, no cell cycle arrest was observed upon treatment.
Total phenolic and flavonoids content
The results (Table 1) revealed that the bioactive EA fraction
of seed extract of E. jambolana had a comparatively lower con-
tent of phenolic compounds (18.54mg GAE/100 g of extract) in
comparison to the flavonoids content (122.32mg EQ/g
of extract). Whereas the EA fraction of root extract of M.
Figure 3. Effects of plant extracts on neovasculature in the rat cornea and chick embryo CAM assays. (a) Representative photographs of VEGF-induced rat corneal neo-
vascularization, plant extracts 20lg/hydron polymer pellet were surgically implanted into the micro-pocket in the cornea of one eye. On day 7, the extent of neovas-
cularization or inhibition was visualized and photographed under a dissection microscope. (b) Quantitative comparison of the number of neovascular vessels per mm2
was estimated. (c) Representative photographs of VEGF-induced neovascularization in shell-less CAM of chicken embryos. Plant extracts, 20lg/filter disc was placed on
the CAM of 6-day old chicken embryos. After 72 h of incubation, the area surrounding the filter disc was inspected for changes in neovascularization. (d) Quantitative
comparison of the number of neovascular branches surrounding the plant extract containing filter paper discs. The data shown represent the results of experiments
that were performed using a maximum of 5 eggs in each group. All quantitative data are presented as mean± SEM of five independent counts; p< 0.01.
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paradisiaca showed high phenolic compounds content (118mg
GAE/100 g of extract) in comparison to the flavonoids (78mg
EQ/g of extract).
Discussion
Sustained angiogenesis, being a hallmark of cancer, has a funda-
mental role in tumour growth, invasion and metastasis. In patho-
logical conditions like chronic inflammation, diabetic
retinopathy, rheumatoid arthritis or atherosclerosis, angiogenesis
is typically upregulated (Quesada et al. 2006). Thus, the prime
importance and the understanding of new blood vessels forma-
tion have led to novel therapies designed to interrupt this process
(Miller et al. 2001). As part of our search for a natural product
based anti-angiogenic agents, we studied the effects of the four
plant extracts; EA and NB fractions from seeds of Eugenia jam-
bolana, EA fraction from the roots of Musa paradisiaca and EA
fraction from leaves of Coccinia indica.
Various bioactive chemical compounds of plant origin may
influence the angiogenic potential of various cell types and hence
upsets the formation of blood vessels (Loboda et al. 2005; Neal
et al. 2006). Several alkaloids such as sanguinarine, isolated from
the root of Sanguinaria canadensis L. (Papaveraceae) and vinca
alkaloids obtained from Catharanthus roseus (L.) G. Don
(Apocynaceae) have been exploited to target angiogenesis (Eun &
Koh 2004; Ribatti et al. 2005). Halofuginone, an alkaloid isolated
from Dichroa febrifuga Lour. (Hydrangeaceae), is a potent inhibi-
tor of crucial steps in angiogenesis cascade (Elkin et al. 2000).
The primary strategy for the screening of novel anti-angiogenic
compounds is to look for EC growth inhibitors (Quesada et al.
2006). Also, the invasive ability of the EC requires extracellular
matrix degradation and involves the activation of many EC sig-
nalling pathways which can also be studied. Pharmacologically
important bioactive organic compounds such as phenols, flavo-
noids, tannins, saponins, and terpenes have better solubility in
solvents such as ethyl acetate and n-butanol. Hence in this study,
we screened the plant extracts obtained from the EA and NB
fractions. Furthermore, we chose to study the anti-angiogenic
property of these extracts based on our previous work on anti-
oxidant and antidiabetic properties of these extracts (Mallick
et al. 2006, 2009; Ghosh 2015). The preliminary toxicity profile
of all the four plant extracts exhibited cytotoxicity in a dose-
dependent manner as assessed by MTT assay. However, EA frac-
tion of E. jambolana and EA fraction of M. paradisiaca showed
high cytotoxicity with lower IC50 values compared to NB fraction
of E. jambolana or EA fraction of C. indica. Subsequently,
our studies with a subtoxic concentration of all the extracts on
Figure 4. Effects of plant extracts on the secretion of VEGF in ascites fluid of tumour bearing mouse. Indirect ELISA was carried out using the ascites fluid harvested
from the control (tumour bearing) and plant extracts treated (100mg/kg body weight) mice to quantify the VEGF in ascites fluid using anti-VEGF165 antibodies. (a)
ELISA standard curve for VEGF. (b) The histogram showing a comparison of VEGF levels in the ascites of untreated control and treated groups. Data are representative
of three independent experiments and values are expressed in mean± SEM, p< 0.01 and p< 0.05.
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the cell proliferation assay using a normal cell line (HUVEC)
and two breast cancer cell lines (MCF-7 and MDA-MB-231)
revealed a significant reduction in rate of cell proliferation even
in the presence of a potent cytokine-VEGF, which may suggest
the interference of VEGF signalling by the bioactive constituents
in the plant extracts. Numerous plant compounds possess anti--
angiogenic property by disrupting angiogenesis signalling cascade
(Lee et al. 2015), like the capsaicin, curcumin or quercetin-medi-
ated inhibition of VEGF-induced angiogenesis (Gururaj et al.
2002; Min et al. 2004; Pratheeshkumar et al. 2012).
The inhibition of tumour angiogenesis, growth and metastasis
by means of phytochemicals is reportedly due to the regulation
of signalling pathways of VEGFR (Fukuda et al. 2006). Thus, to
further inspect whether this curtailment in the rate of cell prolif-
eration was directly due to cytotoxicity or an inherent anti-angio-
genic property, the in vitro endothelial tube formation assay was
performed using HUVECs in presence of VEGF. Our results
showed that both the EA fraction of E. jambolana and EA
fraction of M. paradisiaca were indeed anti-angiogenic and
effectively blocked VEGF-induced angiogenesis in vitro.
To further validate these results, the next step was to evaluate
the antitumor, anti-proliferative and anti-angiogenic properties of
these extracts in vivo. Hence, we adopted the murine mammary
carcinoma, EAT model for the study. The in vivo data showed a
drastic reduction in tumour burden, EAT cell number, ascites
formation and also secreted VEGF levels which bear significant
importance in terms of a clinical correlation with inhibited asci-
tes formation in human tumours. The concomitant reduction in
the peritoneal neovasculature and corresponding decrease in the
MVD was observed in the peritoneum of the treated mice.
The substantiation of the anti-angiogenic property of the two
plant extracts further led us to perform the classical in vivo and
ex vivo angiogenic assays, namely, the rat corneal micro-pocket
assay and shell-less CAM assay (Wang et al. 2004), respectively.
The results of these two experiments were consistent with the
earlier results where the number of new blood vessels was
Table 1. The phytochemical analysis (total phenol and flavonoids content) of the two plant extracts, namely, EA fraction of Eugenia jambolana and EA fraction of
Musa paradisiaca were performed and the values obtained are as shown.
Plant extract Total phenolic content (mg GAE/g dried extract Total flavonoids (lg EQ/g dried extract)
Ethyl acetate fraction of seed of E. jambolana 18.54 122.32
Ethyl acetate fraction of root of M. paradisiaca 118 78
GAE: Gallic acid equivalents; EQ: Quercertin equivalents; E. jambolana: Eugenia jambolana; M. paradisiaca: Musa paradisiaca.
Figure 5. Apoptosis induction and cell cycle analysis of plant extract treated EAT cells. (a) In vivo treated EAT cells with or without plant extracts were stained with
acridine orange and ethidium bromide and verified for apoptotic characteristics such as plasma membrane blebbing, chromatin condensation and apoptotic body for-
mation under a fluorescence microscope. (b) Effect of plant extracts on cell cycle progression. EAT cells, in vitro, were treated with or without different plant extracts
(20lg/mL). After 24 h of treatment, distribution of cell cycle phases and apoptotic cell population was quantitated based on flow cytometric analysis. (c) A quantitative
comparison of the number of apoptotic cells in 10 random fields. (d) Bar diagram showing the percentage of cells present in different phases of cell cycle.
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significantly decreased upon treatment with EA fraction of E.
jambolana or EA fraction of M. paradisiaca, in comparison to
VEGF treatment that showed increased neoangiogenesis.
Furthermore, apart from the anti-angiogenic activity of the
plant extracts, the EAT cells harvested after in vivo treatment
interestingly showed induction of cell death by apoptosis, which
was rather pronounced in the EA fraction of E. jambolana and
EA fraction of M. paradisiaca, confirmed by the AO/EtBr dual
stained morphological study and also by the cell cycle analysis.
These results suggest that the extracts may also contain potent
pro-apoptotic compounds.
The plant extracts showing significant bioactivity could be
attributed to the high flavonoid content in E. jambolana seeds,
since flavonoids have been reported to reduce the risk of devel-
opment of breast cancer and prostate cancer by induction of
apoptosis, reducing oxidative stress (Afsar et al. 2016) and also
inhibit VEGF-induced cell proliferation and migration in
HUVECs, as well as angiogenesis (Wu et al. 2012). Also, the high
phenolic content in the M. paradisiaca roots may be contributing
to the anti-angiogenic, anti-proliferative and pro-apoptotic prop-
erties since phenols have been known to play a critical role in
inhibition of VEGF, PDGF receptor phosphorylation, MMP
inhibition, cell migration, inhibition of ROS (Sun et al. 2015)
and also induction of apoptosis in cancer cells (Roy et al. 2002).
Conclusions
Taken together, representing the sequential events in the angio-
genic process, the two plant extracts, namely, EA fractions of E.
jambolana seeds and M. paradisiaca roots, showed strong anti-
proliferative and anti-angiogenic effects in breast cancer cell lines
through the inhibition of VEGF-induced cell proliferation,
HUVEC tube formation in vitro as well as suppression of VEGF-
induced rat corneal neovascularization in vivo and also CAM
neovascularisation ex vivo. In addition, in the in vivo EAT mouse
tumour model, there was a profound reduction in EAT tumour
growth, ascites volume, ascites VEGF levels, tumour cell number
and also peritoneal angiogenesis. The anti-proliferative effect was
evident in the EAT cells, which clearly showed cell death by
induction of apoptosis. Thus, in conclusion, all the results advo-
cate an authenticated evidence that the two plant extracts have a
potent therapeutic potential in the treatment of cancer or angio-
genesis-related disorders. The findings of this study contribute to
the pharmacological knowledge and the therapeutic efficacy of E.
jambolana and M. paradisiaca, and can initiate the development
of new anti-angiogenic drugs. However, further studies to iden-
tify the individual bioactive compounds and their translational
research is essential to elucidate their explicit mechanisms.
Disclosure statement
The authors report no declaration of interest.
Funding
The University Grants Commission Special Assistance Programme
Department of Special Assistance (UGC-SPA-DSA) Government of
India [No. f 4-1/2013(SAP-II)] is acknowledged.
ORCID
Harsha Raj M. http://orcid.org/0000-0002-4316-4959
References
Afsar T, Trembley JH, Salomon CE, Razak S, Khan MR, Ahmed K. 2016.
Growth inhibition and apoptosis in cancer cells induced by polyphenolic
compounds of Acacia hydaspica: involvement of multiple signal transduc-
tion pathways. Sci Rep. 6:23077.
Ali EM, Sheta M, El Mohsen MA. 2011. Elevated serum and tissue VEGF
associated with poor outcome in breast cancer patients. Alexandria J Med.
47:217–224.
Andzi-Barhe T, Massala KK, Obame LC, Engonga JL. 2015. Phytochemical
studies, total phenolic and flavonoids content and evaluation of antiradical
activity of the extracts of the leaves from Dischistocalyx sp. (Acanthaceae).
J Pharmacogn Phytochem. 3:174–178.
Baliga MS. 2011. Anticancer, chemopreventive and radioprotective potential
of black plum (Eugenia jambolana Lam.). Asian Pac J Cancer Prev.
12:3–15.
Bikfalvi A, Bicknell R. 2002. Recent advances in angiogenesis, anti-angiogen-
esis and vascular targeting. Trends Pharmacol Sci. 23:576–582.
Carbajo-Pescador S, Ordonez R, Benet M, Jover R, Garcıa-Palomo A, Mauriz
JL, Gonzalez-Gallego J. 2013. Inhibition of VEGF expression through
blockade of Hif1a and STAT3 signalling mediates the anti-angiogenic
effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 109:83–91.
Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications
of angiogenesis. Nature. 473:298–307.
Chatterjee K, Ali KM, Ghosh D. 2009. Antihyperglycaemic, antioxidative
activities of a formulated polyherbal drug MTEC (Modified) in streptozo-
tocin-induced diabetic rat. J Med Plant Res. 3:468–480.
Claesson-Welsh L, Welsh M. 2013. VEGFA and tumor angiogenesis. J Intern
Med. 273:14–127.
Dent SF. 2009. The role of VEGF in triple-negative breast cancer: where do
we go from here? Ann Oncol. 20:1615–1617.
Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, Dou HL, Pines
M, Vlodavsky I. 2000. Halofuginone: a potent inhibitor of critical steps in
angiogenesis progression. FASEB J. 14:2477–2485.
Eun JP, Koh GY. 2004. Suppression of angiogenesis by the plant alkaloid,
sanguinarine. Biochem Biophys Res Commun. 317:618–624.
Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN. 2006. Angiogenesis: from
plants to blood vessels. Trends Pharmacol Sci. 27:297–309.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M,
Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int
J Cancer. 136:359–386.
Fukuda S, Kaga S, Zhan L, Bagchi D, Das DK, Bertelli A, Maulik N. 2006.
Resveratrol ameliorates myocardial damage by inducing vascular endothe-
lial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell
Biochem Biophys. 44:43–49.
Ghosh D. 2015. In vitro antioxidant potential of ethyl acetate fraction of seed
of Eugenia jambolana. Asian J Pharm Clin Res. 8:167–170.
Goel HL, Mercurio AM. 2013. VEGF targets the tumour cell. Nat Rev
Cancer. 13:871–882.
Gordaliza M. 2007. Natural products as leads to anticancer drugs. Clin Transl
Oncol. 9:767–776.
Guo C, Buranych A, Sarkar D, Fisher PB, Wang XY. 2013. The role of
tumor-associated macrophages in tumor vascularization. Vasc Cell. 5:1–20.
Gururaj AE, Belakavadi M, Venkatesh DA, Marme D, Salimath BP. 2002.
Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem
Biophys Res Commun. 97:934–942.
Hojjat-Farsangi M. 2014. Small-molecule inhibitors of the receptor tyrosine
kinases: promising tools for targeted cancer therapies. Int J Mol Sci.
15:13768–13801.
Lee JS, Shukla S, Kim JA, Kim M. 2015. Anti-angiogenic effect of Nelumbo
nucifera leaf extracts in human umbilical vein endothelial cells with anti-
oxidant potential. PLoS One. 10:e0118552.
Lingaraju SM, Keshavaiah K, Salimath BP. 2008. Inhibition of in vivo angio-
genesis by Anacardium occidentale L. involves repression of the cytokine
VEGF gene expression. Drug Discov Ther. 2:234–244.
Loboda A, Jazwa A, Wegiel B, Jozkowicz A, Dulak J. 2005. Heme oxygenase-
1-dependent and -independent regulation of angiogenic genes expression:
effect of cobalt protoporphyrin and cobalt chloride on VEGF and IL-8
synthesis in human microvascular endothelial cells. Cell Mol Biol. 51:347.
Lu K, Bhat M, Basu S. 2016. Plants and their active compounds: natural mol-
ecules to target angiogenesis. Angiogenesis. 19:287–295.
Mallick C, De D, Ghosh D. 2009. Correction of protein metabolic disorders
by composite extract of Musa paradisiaca and Coccinia indica in strepto-
zotocin-induced diabetic albino rat: an approach through the pancreas.
Pancreas. 38:322–329.
1498 H. R. M ET AL.
Mallick C, Maiti R, Ghosh D. 2006. Antidiabetogenic effects of separate and
composite extract of seed of Jamun (Eugenia jambolana) and root of
Kadali (Musa paradisiaca) in streptozotocin-induced diabetic male albino
rat: a comparative study. Int J Pharmacol. 2:492–503.
Miao S, Shi X, Zhang H, Wang S, Sun J, Hua W, Miao Q, Zhao Y, Zhang C.
2011. Proliferation-attenuating and apoptosis-inducing effects of tryptan-
thrin on human chronic myeloid leukemia K562 cell line in vitro. Int J
Mol Sci. 12:3831–3845.
Miller KD, Rahman ZU, Sledge Jr GW. 2001. Selection bias in clinical trials.
Breast Dis. 14:31–40.
Min JK, Han KY, Kim EC, Kim YM, Lee SW, Kim OH, Kim KW, Gho YS,
Kwon YG. 2004. Capsaicin inhibits in vitro and in vivo angiogenesis.
Cancer Res. 64:644–651.
Nadumane VK, Timsina B. 2014. Anti-cancer potential of banana flower
extract: an in vitro study. Bangladesh J. Pharmacol. 9:628–635.
Nagaraj SRM, Shilpa P, Rachaiah K, Salimath BP. 2015. Crosstalk between
VEGF and MTA1 signaling pathways contribute to aggressiveness of
breast carcinoma. Mol Carcinog. 54:333–350.
Nataraj NB, Salimath BP. 2013. Crosstalk between VEGF and novel angio-
genic protein regulates tumor angiogenesis and contributes to aggressive-
ness of breast carcinoma. Cell Signal. 25:277–294.
Neal C, Berry D, Doucas H, Manson M, Steward W, Garcea G. 2006.
Clinical aspects of natural anti-angiogenic drugs. Curr Drug Targets.
7:371–383.
Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L,
Hitron A, Lee JC, Xu M, et al. 2012. Quercetin inhibits angiogenesis medi-
ated human prostate tumor growth by targeting VEGFR- 2 regulated
AKT/mTOR/P70S6K signaling pathways. PloS One. 7:e47516.
Pekamwar S, Kalyankar T, Kokate S. 2013. Pharmacological activities of
Coccinia grandis. J Appl Pharm Sci. 3:114–119.
Quesada AR, Mu~noz-Chapuli R, Medina MA. 2006. Anti-angiogenic drugs:
from bench to clinical trials. Med Res Rev. 26:483–530.
Raj MH, Yashaswini B, R€ossler J, Salimath BP. 2016. Combinatorial treatment
with anacardic acid followed by TRAIL augments induction of apoptosis
in TRAIL resistant cancer cells by the regulation of p53, MAPK and NFjb
pathways. Apoptosis. 21:578–593.
Ramachandra S, D'Souza SS, Gururaj AE, Shaila MS, Salimath BP. 2009.
Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites
tumor cells and therapy using sFLT-1 inhibits ascites tumor growth
in vivo. J Gene Med. 11:422–434.
Ribatti D, Finato N, Crivellato E, Marzullo A, Mangieri D, Nico B, Vacca A,
Beltrami CA. 2005. Neovascularization and mast cells with tryptase activity
increase simultaneously with pathologic progression in human endometrial
cancer. Am J Obstet Gynecol. 193:1961–1965.
Roy M, Chakraborty S, Siddiqi M, Bhattacharya RK. 2002. Induction of apop-
tosis in tumor cells by natural phenolic compounds. Asian Pac J Cancer
Prev. 3:61–67.
Shivakumar S, Prabhakar BT, Jayashree K, Rajan MGR, Salimath BP. 2009.
Evaluation of serum vascular endothelial growth factor (VEGF) and
microvessel density (MVD) as prognostic indicators in carcinoma breast.
J Cancer Res Clin Oncol. 135:627–636.
Steeg PS. 2006. Tumor metastasis: mechanistic insights and clinical chal-
lenges. Nat Med. 12:895–904.
Sun Q, Heilmann J, K€onig B. 2015. Natural phenolic metabolites with anti-
angiogenic properties – a review from the chemical point of view.
Beilstein J Org Chem. 11:249–264.
Wagner H, Bladt S. 1996. Plant drug analysis: a thin layer chromatography
atlas. Peabody, MA: Hendrickson Publishers.
Wang S, Zheng Z, Weng Y, Yu Y, Zhang D, Fan W, Dai R, Hu Z. 2004.
Angiogenesis and anti-angiogenesis activity of Chinese medicinal herbal
extracts. Life Sci. 74:2467–2478.
Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, Das
SK, Basu R, McLean B, Kandalam V, et al. 2013. Loss of Apelin exacer-
bates myocardial infarction adverse remodeling and ischemia-reperfusion
injury: therapeutic potential of synthetic Apelin analogs. J Am Heart
Assoc. 2:e000249.
Wu WB, Hung DK, Chang FW, Ong ET, Chen BH. 2012. Anti-inflammatory
and anti-angiogenic effects of flavonoids isolated from Lycium barbarum
Linnaeus on human umbilical vein endothelial cells. Food Funct.
3:1068–1081.
Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX,
Shen ZZ. 2009. Clinicopathological features of the triple-negative tumors
in Chinese breast cancer patients. Breast Cancer Res Treat 115:325–333.
Yu ST, Chen TM, Chern JW, Tseng SY, Chen YH. 2009. Downregulation of
GSTpi expression by tryptanthrin contributing to sensitization of doxo-
rubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-medi-
ated apoptosis. Anticancer Drugs. 20:382–388.
PHARMACEUTICAL BIOLOGY 1499
